Goldman Sachs Lifts Estimates and Price Target on Alexion Pharmaceuticals (ALXN)
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Price: $182.01 --0%
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Goldman Sachs raised estimates and its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) from $56 to $64 following results, suggesting 13% upside.
The firm said the results increased their confidence in continued outperformance driven by: Revenue and EPS growth is organic and sustainable; Execution continues to be noteworthy; Expanded indications likely to increase Soliris's potential.
The firm raised 2011/2012/2013/2014/2015 non-GAAP EPS estimates to $1.16/$1.40/ $1.95/$2.55/$3.08 from $1.17/$1.44/$1.89/$2.41/$2.83.
For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $56.77 yesterday.
The firm said the results increased their confidence in continued outperformance driven by: Revenue and EPS growth is organic and sustainable; Execution continues to be noteworthy; Expanded indications likely to increase Soliris's potential.
The firm raised 2011/2012/2013/2014/2015 non-GAAP EPS estimates to $1.16/$1.40/ $1.95/$2.55/$3.08 from $1.17/$1.44/$1.89/$2.41/$2.83.
For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $56.77 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
